Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:TRIL
Delisted

Trillium Therapeutics Inc. Stock Price (Quote)

$18.44
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $18.44 $18.44 Friday, 27th May 2022 TRIL stock ended at $18.44. During the day the stock fluctuated 0% from a day low at $18.44 to a day high of $18.44.
90 days $18.44 $18.44
52 weeks $5.80 $18.49

Historical Trillium Therapeutics Inc. prices

Date Open High Low Close Volume
Oct 22, 2021 $17.88 $17.94 $17.80 $17.91 655 300
Oct 21, 2021 $17.75 $17.91 $17.75 $17.86 2 818 821
Oct 20, 2021 $17.65 $17.75 $17.61 $17.75 375 700
Oct 19, 2021 $17.53 $17.75 $17.51 $17.67 625 670
Oct 18, 2021 $17.50 $17.57 $17.50 $17.55 743 584
Oct 15, 2021 $17.65 $17.70 $17.50 $17.50 1 050 400
Oct 14, 2021 $17.54 $17.67 $17.49 $17.58 797 500
Oct 13, 2021 $17.60 $17.68 $17.55 $17.55 2 859 000
Oct 12, 2021 $17.87 $17.90 $17.75 $17.76 2 036 492
Oct 11, 2021 $17.79 $17.91 $17.73 $17.91 685 672
Oct 08, 2021 $17.87 $17.93 $17.69 $17.76 2 044 200
Oct 07, 2021 $17.66 $17.88 $17.62 $17.87 803 100
Oct 06, 2021 $17.72 $17.77 $17.60 $17.62 1 193 800
Oct 05, 2021 $17.62 $17.82 $17.60 $17.74 892 200
Oct 04, 2021 $17.61 $17.68 $17.52 $17.64 1 165 900
Oct 01, 2021 $17.57 $17.76 $17.53 $17.64 1 601 000
Sep 30, 2021 $17.84 $17.84 $17.46 $17.56 2 311 600
Sep 29, 2021 $17.80 $17.88 $17.75 $17.77 1 018 800
Sep 28, 2021 $17.64 $17.86 $17.59 $17.80 1 050 200
Sep 27, 2021 $17.56 $17.77 $17.52 $17.73 1 250 500
Sep 24, 2021 $17.38 $17.55 $17.38 $17.53 703 900
Sep 23, 2021 $17.47 $17.65 $17.39 $17.45 1 817 100
Sep 22, 2021 $17.29 $17.50 $17.29 $17.49 1 467 500
Sep 21, 2021 $17.30 $17.34 $17.25 $17.29 1 400 100
Sep 20, 2021 $17.25 $17.34 $17.22 $17.30 2 067 300
Click to get the best stock tips daily for free!

About Trillium Therapeutics Inc.

Trillium Therapeutics. Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The com... TRIL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT